ETF Channel Analyst Sees RSSL Reaching $109, Analysts Expect 19.46% Upside
ByAinvest
Tuesday, Aug 26, 2025 8:24 am ET1min read
DMAC--
One such holding is Alpha Teknova Inc (TKNO), which has an implied analyst target price of $25.00 per share, indicating a 40.70% upside from its recent trading price of $17.75. This substantial upside suggests that analysts are optimistic about the company's future performance and growth prospects.
Another notable holding is DiaMedica Therapeutics Inc (DMAC), with an implied analyst target price of $12.00 per share, representing a 36.15% upside from its recent trading price of $8.80. Analysts' optimism for this biotechnology company is likely driven by its innovative drug pipeline and potential for significant growth in the healthcare sector.
Additionally, Nano-X Imaging Ltd (NNOX) has an implied analyst target price of $1.50 per share, indicating a 35.00% upside from its recent trading price of $1.10. Analysts' confidence in this healthcare technology company is likely due to its advanced imaging technology and potential applications in various medical fields.
While these target prices suggest strong analyst sentiment, it is essential for investors to conduct their own research and consider the broader market conditions and company-specific developments. Analyst targets can be influenced by various factors, and it is crucial to assess whether these targets are justified or if they reflect overly optimistic expectations.
References:
[1] https://www.nasdaq.com/articles/analysts-see-21-gains-ahead-vtwg
NNOX--
TKNO--
The Global X Russell 2000 ETF (RSSL) has a weighted average implied analyst target price of $108.98 per unit, indicating a 19.46% upside from its recent trading price of $91.22. Key holdings with notable upside to their analyst target prices include Alpha Teknova Inc (TKNO), DiaMedica Therapeutics Inc (DMAC), and Nano-X Imaging Ltd (NNOX).
The Global X Russell 2000 ETF (RSSL) has garnered attention from analysts who see significant upside potential in the fund's holdings. With a weighted average implied analyst target price of $108.98 per unit, this represents a 19.46% upside from the ETF's recent trading price of $91.22 [1]. This optimism is driven by several key holdings within the ETF, each with notable upside to their analyst target prices.One such holding is Alpha Teknova Inc (TKNO), which has an implied analyst target price of $25.00 per share, indicating a 40.70% upside from its recent trading price of $17.75. This substantial upside suggests that analysts are optimistic about the company's future performance and growth prospects.
Another notable holding is DiaMedica Therapeutics Inc (DMAC), with an implied analyst target price of $12.00 per share, representing a 36.15% upside from its recent trading price of $8.80. Analysts' optimism for this biotechnology company is likely driven by its innovative drug pipeline and potential for significant growth in the healthcare sector.
Additionally, Nano-X Imaging Ltd (NNOX) has an implied analyst target price of $1.50 per share, indicating a 35.00% upside from its recent trading price of $1.10. Analysts' confidence in this healthcare technology company is likely due to its advanced imaging technology and potential applications in various medical fields.
While these target prices suggest strong analyst sentiment, it is essential for investors to conduct their own research and consider the broader market conditions and company-specific developments. Analyst targets can be influenced by various factors, and it is crucial to assess whether these targets are justified or if they reflect overly optimistic expectations.
References:
[1] https://www.nasdaq.com/articles/analysts-see-21-gains-ahead-vtwg
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet